Sodium Glucose Cotransporter 2 (SGLT2) Plays as a Physiological Glucose Sensor and Regulates Cellular Contractility in Rat Mesangial Cells

por Wakisaka, Masanori, Nagao, Tetsuhiko, Yoshinari, Mototaka
Publicado 2016

Lessons from the Trials for the Desirable Effects of Sodium Glucose Co-Transporter 2 Inhibitors on Diabetic Cardiovascular Events and Renal Dysfunction

por Wakisaka, Masanori, Kamouchi, Masahiro, Kitazono, Takanari
Publicado 2019

Recovery from Diabetic Macular Edema in a Diabetic Patient After Minimal Dose of a Sodium Glucose Co-Transporter 2 Inhibitor

por Yoshizumi, Hideyuki, Ejima, Tetsushi, Nagao, Tetsuhiko, Wakisaka, Masanori
Publicado 2018

Roles of Sodium-Glucose Cotransporter 2 of Mesangial Cells in Diabetic Kidney Disease

por Wakisaka, Masanori, Nakamura, Kuniyuki, Nakano, Toshiaki, Kitazono, Takanari
Publicado 2021

Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells

por Maki, Toshinobu, Maeno, Sayaka, Maeda, Yasutaka, Yamato, Mayumi, Sonoda, Noriyuki, Ogawa, Yoshihiro, Wakisaka, Masanori, Inoguchi, Toyoshi
Publicado 2019

Low-dose sodium-glucose cotransporter 2 inhibitor ameliorates ischemic brain injury in mice through pericyte protection without glucose-lowering effects

por Takashima, Masamitsu, Nakamura, Kuniyuki, Kiyohara, Takuya, Wakisaka, Yoshinobu, Hidaka, Masaoki, Takaki, Hayato, Yamanaka, Kei, Shibahara, Tomoya, Wakisaka, Masanori, Ago, Tetsuro, Kitazono, Takanari
Publicado 2022